This trial will test the hypothesis that aflibercept intravitreal injections given on a variable dosing regimen is associated with lower aqueous cytokine levels and longer treatment intervals in patients with neovascular age-related macular degeneration, macular edema secondary to retinal vein occlusion and diabetic macular edema.
- Macular Edema
- Retinal Vein Occlusion
- Diabetic Macular Edema
- Age-Related Macular Degeneration
1 Primary · 6 Secondary · Reporting Duration: month 2, at the visits closest to injection of months 6, 12 and 18.
0 Treatment Group
168 Total Participants · 0 Treatment Group
Primary Treatment: Treatment · No Placebo Group · Phase 4
Who is running the clinical trial?
Age 18+ · All Participants · 3 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
How many subjects are participatng in this experiment?
"Indeed, it appears that recruitment is open for this clinical trial. The details of which were first uploaded on February 28th 2017 and last revised April 27th 2021, calling for 168 participants to be enrolled at two different medical centers." - Anonymous Online Contributor
What safety precautions should patients take before undergoing this treatment regimen?
"This treatment has been assessed to be safe and was given a rating of 3. This is because it has obtained approval as an end-stage clinical trial." - Anonymous Online Contributor
What type of conditions is this intervention commonly prescribed for?
"Wet age-related [macular degeneration](https://www.withpower.com/clinical-trials/macular-degeneration) (wAMD) is primarily treated with this medication. Additionally, it can be used to ameliorate symptoms of other conditions including Macular edema, Diabetic Macular Edema (DME), and Macular Degeneration." - Anonymous Online Contributor
Are there any spots available to join this research endeavor?
"Affirmative. Clinicaltrials.gov details that the clinical trial is currently recruiting, with its initial posting on February 28th 2017 and latest revision occurring April 27th 2021. 168 participants will be accepted from 2 medical centres." - Anonymous Online Contributor